[go: up one dir, main page]

CO4870792A1 - Compuestos y conjunto de medios de diagnostico para detectar y vigilar la progresion de cancer de prostata - Google Patents

Compuestos y conjunto de medios de diagnostico para detectar y vigilar la progresion de cancer de prostata

Info

Publication number
CO4870792A1
CO4870792A1 CO98010253A CO98010253A CO4870792A1 CO 4870792 A1 CO4870792 A1 CO 4870792A1 CO 98010253 A CO98010253 A CO 98010253A CO 98010253 A CO98010253 A CO 98010253A CO 4870792 A1 CO4870792 A1 CO 4870792A1
Authority
CO
Colombia
Prior art keywords
polypeptide
nucleotide sequences
patient
protein
prostate
Prior art date
Application number
CO98010253A
Other languages
English (en)
Inventor
Jiangchun Xu
David C Dillon
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of CO4870792A1 publication Critical patent/CO4870792A1/es

Links

Classifications

    • G01N33/57555—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método para detectar el cáncer de próstata en un paciente,que comprende: (a) colocar en contacto una muestra biológica obtenida de un paciente con un agente de enlace que es capaz de enlazar a un polipéptido, el polipéptido que comprende una porción inmunogénica de una proteína de próstata o una variante de ella, donde la dicha proteína comprende una secuencia de aminoácidos codificada por una molécula de ADN que tiene una secuencia seleccionada a partir del grupo que consiste de secuencias de nucleótidos citadas en las SEQ ID Nos. 2 a 3, 5 a 107, 109 a 111, 115 a 171, 173 a 175, 177, 179 a 224, los complementos de dichas secuencias de nucleótidos y variantes de dichas secuencias de nucleótidos; y (b) detectar en la muestra una proteína o polipéptido que enlaza al agente de enlace, detectando consecuentemente el cáncer de próstata en un paciente.Un método para vigilar la progresión del cáncer de prostata en un paciente, que comprende: (a) colocar en contacto una muestra biológica obtenida de un paciente con un agente de enlace que es capaz de enlazar a un polipéptido, dicho polipéptido que comprende una porción inmunogénica de una proteína de próstata o una variante de ella, donde la dicha proteína comprende una secuencia de aminoácidos codificada por una molécula de ADN que tiene una secuencia seleccionada a partir del grupo que consiste de secuencias de nucleótidos citadas en las SEQ ID Nos. 2 a 3, 5 a 107, 109 a 111, 115 a 171, 173 a 175, 177, 179 a 224, los complementos de dichas secuencias de nucleótidos y variantes de dichas secuencias de nucleótidos; y (b) determinar en la muestra una cantidad de una proteína o polipéptido que enlaza al agente de enlace; (c) repetir los pasos (a) y (b) cada 24 a 27 horas durante un período de 6 meses a 1 año, y a partir de entonces hacerlos cuando se considere necesario; y (d) comparar la cantidad de polipéptidos detectada en los pasos (b) y (c) para vigilar la progresión del cáncer de prostata en el paciente.1Un conjunto de medios de diagnóstico que comprende: (a) uno o más anticuerpos monoclonales que enlazan a un polipéptido codificado por una molécula de ADN que tiene una secuencia de nucleótidos seleccionada a partir del grupo que consiste de las SEQ ID Nos. 5 a 7, 30 a 40, 46, 53, 66 a 69, 71, 72, 75 a 78, 80, 82 a 86, 88, 89, 91, 94 a 96, 98 a 102, 105, 106, 161 a 170, 179, 180, 182 a 187, 189, 190, 192, 195 a 197, 199 a 202, 205, 206, los complementos de dichas secuencias y variantes de dichas secuencias de nucleótidos; y (b) un reactivo de detección.
CO98010253A 1997-02-25 1998-02-25 Compuestos y conjunto de medios de diagnostico para detectar y vigilar la progresion de cancer de prostata CO4870792A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80659697A 1997-02-25 1997-02-25
US90480997A 1997-08-01 1997-08-01
US2074798A 1998-02-09 1998-02-09

Publications (1)

Publication Number Publication Date
CO4870792A1 true CO4870792A1 (es) 1999-12-27

Family

ID=27361502

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98010253A CO4870792A1 (es) 1997-02-25 1998-02-25 Compuestos y conjunto de medios de diagnostico para detectar y vigilar la progresion de cancer de prostata

Country Status (13)

Country Link
US (1) US6887660B2 (es)
EP (2) EP0972201B1 (es)
JP (4) JP3844366B2 (es)
AR (1) AR012035A1 (es)
AT (1) ATE302414T1 (es)
BR (1) BR9807734A (es)
CA (1) CA2281954A1 (es)
CO (1) CO4870792A1 (es)
DE (1) DE69831222T2 (es)
DK (1) DK0972201T3 (es)
ES (1) ES2248891T3 (es)
IL (1) IL131539A0 (es)
WO (1) WO1998037418A2 (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7270980B2 (en) * 1997-02-25 2007-09-18 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6262245B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6613872B1 (en) 1997-02-25 2003-09-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6395278B1 (en) 1997-02-25 2002-05-28 Corixa Corporation Prostate specific fusion protein compositions
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6365369B1 (en) 1998-04-01 2002-04-02 Human Genome Sciences, Inc. Prostate specific secreted protein
US6048970A (en) * 1998-05-22 2000-04-11 Incyte Pharmaceuticals, Inc. Prostate growth-associated membrane proteins
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
IL139988A0 (en) * 1998-06-01 2002-02-10 Urogenesys Inc Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
ES2329851T3 (es) 1998-06-01 2009-12-01 Agensys, Inc. Nuevos antigenos transmembranables expresados en canceres humano y utilizacion de los mismos.
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
JP2002520054A (ja) * 1998-07-14 2002-07-09 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
IL142310A0 (en) * 1998-10-02 2002-03-10 Urogenesys Inc Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US7022497B1 (en) * 1999-03-11 2006-04-04 Mt. Sinai Hospital Human kallikrein-like genes
EP1724351A3 (en) * 1999-03-11 2007-11-14 Mount Sinai Hospital Human Kallikrein-like genes
WO2000071711A2 (en) * 1999-05-20 2000-11-30 Fahri Saatcioglu Differentially expressed genes in prostate cancer
CO5450246A1 (es) * 1999-07-13 2004-10-29 Smithkline Beecham Corp Vacuna
US6617109B1 (en) 1999-09-10 2003-09-09 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6720146B2 (en) 1999-09-10 2004-04-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030232056A1 (en) 1999-09-10 2003-12-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6613515B1 (en) 1999-09-10 2003-09-02 Corixa Corporation Ovarian tumor sequences and methods of use therefor
WO2001018046A2 (en) * 1999-09-10 2001-03-15 Corixa Corporation Ovarian tumor sequences and methods of use therefor
US6710170B2 (en) 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
GB9922835D0 (en) * 1999-09-25 1999-11-24 Smithkline Beecham Biolog Novel compounds
AU7994200A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
WO2001025446A1 (en) * 1999-10-07 2001-04-12 Schering Aktiengesellschaft Dna encoding prost 07 polypeptide
JP2004537252A (ja) * 1999-11-12 2004-12-16 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
CN1436234A (zh) * 2000-01-14 2003-08-13 科里克萨有限公司 用于前列腺癌治疗和诊断的组合物及方法
US7611892B2 (en) 2000-03-24 2009-11-03 President And Fellows Of Harvard College Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
EP1311673A2 (en) * 2000-03-27 2003-05-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
RU2276672C2 (ru) * 2000-04-10 2006-05-20 Институт Биоорганической химии им. акад. М.М. Шемякина и Ю.А. Овчинникова Российской Академии Наук Антитело к фактору hldf, способ его получения (варианты), пептид с антигенными и нк-гидролизующими свойствами и способ диагностики анапластического состояния клетки человека
WO2001077682A1 (fr) * 2000-04-10 2001-10-18 Institut Bioorganicheskoi Khimii Imeni Akademikov M.M. Shemyakina I Ju. A. Ovchinnikova Rossiisskoi Akademii Nauk Anticorps diriges contre le facteur hldf, procedes de fabrication correspondants, peptides avec des capacites antigeniques et a hydrolyse hk et procede de diagnostic de l'etat anaplasique de cellules humaines
PT2266603E (pt) 2000-10-18 2012-11-02 Glaxosmithkline Biolog Sa Vacinas tumorais
EP1356108A2 (en) 2000-11-28 2003-10-29 Wyeth Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
JP2004526426A (ja) 2000-11-28 2004-09-02 ワイス 前立腺癌の診断および治療に有用なｋｉａａ核酸およびポリペプチドの発現分析
JP2005505271A (ja) 2001-09-06 2005-02-24 アジェンシス， インコーポレイテッド 癌の処置および検出において有用なｓｔｅａｐ−１と名称が与えられる核酸および対応するタンパク質
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US20040162236A1 (en) * 2002-04-01 2004-08-19 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1792912A3 (en) * 2002-04-02 2007-08-29 Curagen Corporation Novel proteins and nucleic acids encoding same
US20060234227A1 (en) * 2002-05-14 2006-10-19 Alexei Slesarev Helix-hairpin-helix motifs to manipulate properties of dna processing enzymes
JP4643450B2 (ja) 2003-08-08 2011-03-02 株式会社ペルセウスプロテオミクス 癌高発現遺伝子
US7276408B2 (en) * 2003-10-08 2007-10-02 Texas Instruments Incorporated Reduction of dopant loss in a gate structure
WO2005062977A2 (en) * 2003-12-23 2005-07-14 The Regents Of The University Of California Prostate cancer specific internalizing human antibodies
US8008442B2 (en) 2004-04-22 2011-08-30 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
PT2484375T (pt) 2006-09-26 2018-07-09 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
DK2061814T3 (da) 2006-10-27 2012-08-27 Genentech Inc Antistoffer og immunokonjugater og anvendelse deraf.
US8722064B2 (en) 2009-06-05 2014-05-13 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
US20120263754A1 (en) 2011-02-15 2012-10-18 Immune Design Corp. Methods for Enhancing Immunogen Specific Immune Responses by Vectored Vaccines
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
LT2811981T (lt) 2012-02-07 2019-06-10 Infectious Disease Research Institute Pagerintos adjuvanto kompozicijos, apimančios tlr4 agonistus, ir jų panaudojimo būdai
SG11201407586WA (en) 2012-05-16 2014-12-30 Immune Design Corp Vaccines for hsv-2
HK1214510A1 (zh) 2013-04-18 2016-07-29 Immune Design Corp. 用於癌症治疗的gla单一疗法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B1 (en) 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
CA2955015A1 (en) 2014-07-15 2016-01-21 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
WO2017180420A1 (en) 2016-04-11 2017-10-19 Board Of Regents, The University Of Texas System Methods and compositions for detecting single t cell receptor affinity and sequence
MX2018013640A (es) 2016-05-16 2019-08-01 Infectious Disease Res Inst Liposomas pegiladas y metodos de uso.
RU2761870C2 (ru) 2016-05-16 2021-12-13 Инфекшес Дизис Рисёрч Инститьют Состав, содержащий агонист tlr, и способы применения
RU2753874C2 (ru) 2016-06-01 2021-08-24 Инфекшес Дизис Рисёрч Инститьют Наноалюмочастицы, содержащие агент, регулирующий размер
SG11201909218RA (en) 2017-04-03 2019-11-28 Hoffmann La Roche Antibodies binding to steap-1
MX2019015076A (es) 2017-06-15 2020-08-03 Infectious Disease Res Inst Portadores lípidos nanoestructurados y emulsiones estables y usos de los mismos.
JP7339942B2 (ja) 2017-09-08 2023-09-06 アクセス ツー アドバンスト ヘルス インスティチュート サポニンを含むリポソーム製剤および使用方法
KR20220125149A (ko) 2019-05-25 2022-09-14 액세스 투 어드밴스드 헬스 인스티튜트 애주번트 백신 에멀션을 분무 건조시키기 위한 조성물 및 방법
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
AU2021335334A1 (en) 2020-09-04 2023-04-20 Access To Advanced Health Institute Genetically-adjuvanted rna vaccines
KR20230148148A (ko) 2020-12-23 2023-10-24 액세스 투 어드밴스드 헬스 인스티튜트 솔라네솔 백신 보조제 및 이의 제조 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851764A (en) * 1990-10-25 1998-12-22 The Trustees Of Columbia University In The City Of New York Human prostate tumor inducing gene-1 and uses thereof
WO1993014753A1 (en) 1992-01-27 1993-08-05 The Board Of Trustees Of The Leland Stanford Junior University Histamine derivatives and methods for their use
WO1993014775A1 (en) * 1992-01-31 1993-08-05 Wright George L Jr Monoclonal antibody pd41 and antigen associated with prostate adenocarcinomas
US5428011A (en) 1992-06-16 1995-06-27 Procyon Biopharma, Inc. Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma
US5786148A (en) 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
DK0668777T3 (da) * 1992-11-05 2007-02-19 Sloan Kettering Inst Cancer Prostataspecifikt membran-antigen
DE69434475T2 (de) 1993-08-11 2006-05-18 Jenner Technologies, Tiburon Impfstoff gegen prostatakrebs
EP0652014A1 (en) 1993-11-10 1995-05-10 National Institute Of Immunology Treatment of prostatic hypertrophy
WO1995030758A1 (en) 1994-05-10 1995-11-16 Mayo Foundation For Medical Education And Research Recombinant hk2 polypeptide
US6130043A (en) 1997-05-02 2000-10-10 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate

Also Published As

Publication number Publication date
JP3844366B2 (ja) 2006-11-08
CA2281954A1 (en) 1998-08-27
JP2008249727A (ja) 2008-10-16
EP0972201A2 (en) 2000-01-19
JP2001513886A (ja) 2001-09-04
JP2006201187A (ja) 2006-08-03
US6887660B2 (en) 2005-05-03
EP0972201B1 (en) 2005-08-17
WO1998037418A2 (en) 1998-08-27
US20020081580A1 (en) 2002-06-27
AR012035A1 (es) 2000-09-27
IL131539A0 (en) 2001-01-28
DE69831222T2 (de) 2006-07-13
ATE302414T1 (de) 2005-09-15
JP2007114212A (ja) 2007-05-10
BR9807734A (pt) 2000-10-31
EP1630235A2 (en) 2006-03-01
DE69831222D1 (de) 2005-09-22
EP1630235A3 (en) 2009-05-27
ES2248891T3 (es) 2006-03-16
WO1998037418A3 (en) 1999-02-25
DK0972201T3 (da) 2006-01-02

Similar Documents

Publication Publication Date Title
CO4870792A1 (es) Compuestos y conjunto de medios de diagnostico para detectar y vigilar la progresion de cancer de prostata
BR9908567A (pt) Processos de detecção de ácido nucléico zimogênico e moléculas relacionadas e kits
TR200000113T2 (tr) Tüberkülozu teşhis etmek için bileşikler ve bunları kullanma yöntemleri.
SE9500023L (sv) Sätt att detektera cancer
DE69840669D1 (de) Pca3, pca3-gene und verfahren zu ihrer verwendung
JP2008249727A5 (es)
DE69636075D1 (de) Verbindungen und verfahren zur diagnose von tuberkulose
DE69334071D1 (de) Prostata-spezifisches membranantigen
WO1997033909A3 (en) Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
BR0112602A (pt) Compostos e métodos para tratamento e diagnóstico de infecção clamidial
DK0914344T3 (da) Assay og reagenser til kvantificering af hBNP
NL300118I1 (nl) Voor Factor VIIIC coderende DNA-sequenties en verwante DNA-constructen.
DE60043944D1 (de) Zytokin zcyt018
EA200000845A1 (ru) Ген, кодирующий новый маркер рака
ATE433463T1 (de) Monospezifische antikörper gegen fibrinogen und fibrinopeptide b
DK0750637T3 (da) CAI resistens, som koder for et protein, samt anvendelse deraf
WO1999018210A3 (en) Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
DE502004008729D1 (de) Gegen das Prothrombin-Fragment F1+2 gerichtete Antikörper, ihre Herstellung und Verwendung
EP1580265A4 (en) FROM A NEUROBLASTOM IN STAGE 4S ISOLATED LUCES
DE60131962D1 (de) Verfahren und zusammensetzungen zum nachweis von taenia solium larven mittels eines klonierten antigens
RU2206574C2 (ru) Полипептид, содержащий антигенный участок растворимого антигена м. tuberculosis, способ (варианты) и диагностический набор (варианты) для выявления инфекции m. tuberculosis
JP2003532369A5 (es)
ATE440968T1 (de) Verfahren zur diagnostizierung von aspirinunverträglichkeit
WO2001010897A3 (en) Methods and compositions for detecting larval taenia solium
ATE158815T1 (de) Hippurikasegen